$PHIO
Phio Pharmaceuticals Corp Stock $phio

$phio Overview Financials Valuation SEC Filings Company Website

2013 Q1 Form 10-K Financial Statement

#000119312513133515 Filed on March 29, 2013

Income Statement

Concept	2013 Q1	2012 Q4	2011 Q4
Revenue	$53.00K	$40.00K	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$12.93M	$620.0K	$940.0K
YoY Change	1624.0%	-34.04%
% of Gross Profit
Research & Development	$13.77M	$1.140M	$1.550M
YoY Change	1093.33%	-26.45%
% of Gross Profit
Depreciation & Amortization	$26.00K	$30.00K	$40.00K
YoY Change	-35.0%	-25.0%
% of Gross Profit
Operating Expenses	$14.45M	$1.750M	$2.490M
YoY Change	658.37%	-29.72%
Operating Profit	-$14.39M
YoY Change	655.59%
Interest Expense	$0.00	$0.00	$0.00
YoY Change	-100.0%
% of Operating Profit
Other Income/Expense, Net	-$3.000K	$0.00	$40.00K
YoY Change	-400.0%	-100.0%
Pretax Income	-$14.40M	-$1.710M	-$2.450M
YoY Change	646.11%	-30.2%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$14.40M	-$1.710M	-$2.450M
YoY Change	647.51%	-30.2%
Net Earnings / Revenue	-27164.15%	-4275.0%
Basic Earnings Per Share
Diluted Earnings Per Share	-$15.20B	-$2.334B	-$4.483B
COMMON SHARES
Basic Shares Outstanding	321.6M shares	158.7M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2013 Q1	2012 Q4	2011 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$19.64M	$5.130M	$500.0K
YoY Change	5355.56%	926.0%
Cash & Equivalents	$19.64M	$5.127M	$503.0K
Short-Term Investments
Other Short-Term Assets	$150.0K	$260.0K	$240.0K
YoY Change	150.0%	8.33%
Inventory
Prepaid Expenses
Receivables		$0.00	$600.0K
Other Receivables		$0.00	$0.00
Total Short-Term Assets	$19.80M	$5.392M	$1.339M
YoY Change	1860.2%	302.69%
LONG-TERM ASSETS
Property, Plant & Equipment	$172.0K	$198.0K	$355.0K
YoY Change	-46.25%	-44.23%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$0.00	$0.00	$0.00
YoY Change
Total Long-Term Assets	$174.0K	$200.0K	$355.0K
YoY Change	-45.63%	-43.66%
TOTAL ASSETS
Total Short-Term Assets	$19.80M	$5.392M	$1.339M
Total Long-Term Assets	$174.0K	$200.0K	$355.0K
Total Assets	$19.97M	$5.592M	$1.694M
YoY Change	1401.65%	230.11%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$366.0K	$416.0K	$387.0K
YoY Change	-51.2%	7.49%
Accrued Expenses	$1.126M	$767.0K	$544.0K
YoY Change	108.52%	40.99%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00	$10.00K	$30.00K
YoY Change	-100.0%	-66.67%
Total Short-Term Liabilities	$1.958M	$1.679M	$1.776M
YoY Change	-6.76%	-5.46%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$510.0K
YoY Change	-100.0%	-100.0%
Other Long-Term Liabilities	$0.00	$30.00K	$0.00
YoY Change
Total Long-Term Liabilities	$0.00	$30.00K	$510.0K
YoY Change	-100.0%	-94.12%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.958M	$1.679M	$1.776M
Total Long-Term Liabilities	$0.00	$30.00K	$510.0K
Total Liabilities	$1.958M	$1.706M	$2.281M
YoY Change	-36.84%	-25.21%
SHAREHOLDERS EQUITY
Retained Earnings		$17.16M
YoY Change
Common Stock	$32.00K	$16.00K	$10.00K
YoY Change		60.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$8.118M	-$5.840M	-$587.0K
YoY Change
Total Liabilities & Shareholders Equity	$19.97M	$5.592M	$1.694M
YoY Change	1401.65%	230.11%

Cashflow Statement

Concept	2013 Q1	2012 Q4	2011 Q4
OPERATING ACTIVITIES
Net Income	-$14.40M	-$1.710M	-$2.450M
YoY Change	647.51%	-30.2%
Depreciation, Depletion And Amortization	$26.00K	$30.00K	$40.00K
YoY Change	-35.0%	-25.0%
Cash From Operating Activities	-$1.128M	-$1.150M	-$2.810M
YoY Change	-6.7%	-59.07%
INVESTING ACTIVITIES
Capital Expenditures		-$10.00K	-$10.00K
YoY Change		0.0%
Acquisitions
YoY Change
Other Investing Activities		$10.00K	-$50.00K
YoY Change		-120.0%
Cash From Investing Activities		$10.00K	-$60.00K
YoY Change		-116.67%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$15.65M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	15.64M	0.000	2.950M
YoY Change	1448.91%	-100.0%
NET CHANGE
Cash From Operating Activities	-1.128M	-1.150M	-2.810M
Cash From Investing Activities		10.00K	-60.00K
Cash From Financing Activities	15.64M	0.000	2.950M
Net Change In Cash	14.52M	-1.140M	80.00K
YoY Change	-7394.47%	-1525.0%
FREE CASH FLOW
Cash From Operating Activities	-$1.128M	-$1.150M	-$2.810M
Capital Expenditures		-$10.00K	-$10.00K
Free Cash Flow	-$1.128M	-$1.140M	-$2.800M
YoY Change	-6.7%	-59.29%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2012Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1500000000	shares
CY2012Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2012Q1	rxii	Number Of Shares Authorized At Incorporation NumberOfSharesAuthorizedAtIncorporation	1000	shares
CY2013Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	321627134	shares
CY2011Q3	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	1000
CY2011Q3	us-gaap	Derivative Liability Fair Value Net1 DerivativeLiabilityFairValueNet1
CY2011Q3	us-gaap	Derivative Fair Value Of Derivative Liability DerivativeFairValueOfDerivativeLiability	8722000
CY2011Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2011Q3	rxii	Value Of Shares Agreed To Purchase Under Agreement ValueOfSharesAgreedToPurchaseUnderAgreement	9500000
CY2011Q3	rxii	Amount Of Investment AmountOfInvestment	9500000
CY2011Q3	rxii	Onetime Milestone Payment To Be Paid Under Agreement OnetimeMilestonePaymentToBePaidUnderAgreement	350000
CY2011Q3	rxii	Maximum Percentage Of Shares Owned By Stockholders MaximumPercentageOfSharesOwnedByStockholders	0.09999	pure
CY2011Q3	rxii	Number Of Shares Agreed To Purchase Under Agreement NumberOfSharesAgreedToPurchaseUnderAgreement	9500	shares
CY2012Q2	dei	Entity Public Float EntityPublicFloat	10537000
CY2003Q4	us-gaap	Stockholders Equity StockholdersEquity	-89000
CY2004Q4	us-gaap	Stockholders Equity StockholdersEquity	-968000
CY2005Q4	us-gaap	Stockholders Equity StockholdersEquity	-450000
CY2006Q4	us-gaap	Stockholders Equity StockholdersEquity	-268000
CY2007Q4	us-gaap	Stockholders Equity StockholdersEquity	10823000
CY2008Q4	us-gaap	Stockholders Equity StockholdersEquity	8968000
CY2009Q4	us-gaap	Stockholders Equity StockholdersEquity	741000
CY2010Q4	us-gaap	Derivative Liability Fair Value Net1 DerivativeLiabilityFairValueNet1	3138000
CY2010Q4	us-gaap	Stockholders Equity StockholdersEquity	2430000
CY2011Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	1113000
CY2011Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1500000000	shares
CY2011Q4	us-gaap	Due From Affiliate Current DueFromAffiliateCurrent	597000
CY2011Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1776000
CY2011Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	186000
CY2011Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	53000
CY2011Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	816000
CY2011Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	53000
CY2011Q4	us-gaap	Assets Assets	1694000
CY2011Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	53000
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	503000
CY2011Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet
CY2011Q4	us-gaap	Valuation Allowance Amount ValuationAllowanceAmount	1113000
CY2011Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
CY2011Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	500000
CY2011Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber		shares
CY2011Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2011Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	986000
CY2011Q4	us-gaap	Capital Leased Assets Gross CapitalLeasedAssetsGross	236000
CY2011Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1694000
CY2011Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	100439841	shares
CY2011Q4	us-gaap	Common Stock Value CommonStockValue	10000
CY2011Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	1113000
CY2011Q4	us-gaap	Liabilities Liabilities	2281000
CY2011Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	127000
CY2011Q4	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	29000
CY2011Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	544000
CY2011Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	355000
CY2011Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2011Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	100439841	shares
CY2011Q4	us-gaap	Assets Current AssetsCurrent	1339000
CY2011Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	10000000	shares
CY2011Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	3680000
CY2011Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	0	shares
CY2011Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2011Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	93000
CY2011Q4	us-gaap	Property Plant And Equipment Owned Accumulated Depreciation PropertyPlantAndEquipmentOwnedAccumulatedDepreciation	646000
CY2011Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.0001
CY2011Q4	us-gaap	Stockholders Equity StockholdersEquity	-587000
CY2011Q4	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	5000
CY2011Q4	us-gaap	Development Stage Enterprise Deficit Accumulated During Development Stage DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage	4277000
CY2011Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	387000
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	1900
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	0.11
CY2012Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	3501000
CY2012Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1500000000	shares
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	90000000	shares
CY2012Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	138462	shares
CY2012Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2012Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1679000
CY2012Q4	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000
CY2012Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	212000
CY2012Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	53000
CY2012Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	491000
CY2012Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	53000
CY2012Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	17157000
CY2012Q4	us-gaap	Assets Assets	5592000
CY2012Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	53000
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5127000
CY2012Q4	us-gaap	Grants Receivable GrantsReceivable	800000
CY2012Q4	us-gaap	Operating Leases Future Minimum Payments Receivable OperatingLeasesFutureMinimumPaymentsReceivable	70000
CY2012Q4	us-gaap	Deferred Revenue DeferredRevenue	27000
CY2012Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet
CY2012Q4	us-gaap	Valuation Allowance Amount ValuationAllowanceAmount	2387000
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.10
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	63847938	shares
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	26152062	shares
CY2012Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	9726	shares
CY2012Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	3054000
CY2012Q4	us-gaap	Capital Leased Assets Gross CapitalLeasedAssetsGross	26000
CY2012Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	5592000
CY2012Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	158670223	shares
CY2012Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	801362084	shares
CY2012Q4	us-gaap	Common Stock Value CommonStockValue	16000
CY2012Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	3501000
CY2012Q4	us-gaap	Operating Leases Future Minimum Payments Receivable In Two Years OperatingLeasesFutureMinimumPaymentsReceivableInTwoYears	13000
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	4716656	shares
CY2012Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	282000
CY2012Q4	us-gaap	Liabilities Liabilities	1706000
CY2012Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	2000
CY2012Q4	us-gaap	Operating Leases Future Minimum Payments Receivable Current OperatingLeasesFutureMinimumPaymentsReceivableCurrent	57000
CY2012Q4	us-gaap	Temporary Equity Liquidation Preference TemporaryEquityLiquidationPreference	9726000
CY2012Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	105000
CY2012Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2012Q4	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	5000
CY2012Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	767000
CY2012Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	198000
CY2012Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	57000
CY2012Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2012Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	158670223	shares
CY2012Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	3000
CY2012Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	10000000	shares
CY2012Q4	us-gaap	Assets Current AssetsCurrent	5392000
CY2012Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	11301000
CY2012Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	9726	shares
CY2012Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2012Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	17000
CY2012Q4	us-gaap	Property Plant And Equipment Owned Accumulated Depreciation PropertyPlantAndEquipmentOwnedAccumulatedDepreciation	585000
CY2012Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.0001
CY2012Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	9726000
CY2012Q4	us-gaap	Stockholders Equity StockholdersEquity	-5840000
CY2012Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	950
CY2012Q4	us-gaap	Development Stage Enterprise Deficit Accumulated During Development Stage DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage	17157000
CY2012Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	7800000
CY2012Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	416000
CY2012Q4	rxii	Percentage Of Deferred Tax Assets Valuation Allowance PercentageOfDeferredTaxAssetsValuationAllowance	1.00	pure
CY2012Q4	rxii	Number Of Common Shares Reserved For Future Issuance NumberOfCommonSharesReservedForFutureIssuance	711223622	shares
CY2012Q2	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio StockholdersEquityNoteStockSplitConversionRatio	1004397.41	Ratio
CY2012Q2	us-gaap	Stock Issued During Period Shares Stock Splits StockIssuedDuringPeriodSharesStockSplits	66959894	shares
	us-gaap	Increase Decrease In Derivative Assets And Liabilities IncreaseDecreaseInDerivativeAssetsAndLiabilities	-2611000
	rxii	Reclassification Of Derivative Liability Upon Elimination Of Obligation ReclassificationOfDerivativeLiabilityUponEliminationOfObligation	9249000
CY2012Q2	us-gaap	Debt Conversion Converted Instrument Shares Issued1 DebtConversionConvertedInstrumentSharesIssued1	9500	shares
CY2012Q2	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	1000000
	rxii	Cash Contributions From Parent Company CashContributionsFromParentCompany	2000
CY2011Q3	us-gaap	Stock Issued During Period Value Issued For Noncash Considerations StockIssuedDuringPeriodValueIssuedForNoncashConsiderations	1.00
CY2011Q3	us-gaap	Stock Issued During Period Shares Issued For Cash StockIssuedDuringPeriodSharesIssuedForCash	100	shares
CY2011Q3	rxii	Issuance Price Of Initial Shares IssuancePriceOfInitialShares	0.01
CY2011Q3	rxii	Maintenance Costs To Be Paid Under Agreement MaintenanceCostsToBePaidUnderAgreement	100000
CY2011Q3	rxii	Maximum Amount Of Funding MaximumAmountOfFunding	1500000
CY2011Q3	rxii	Percentage Of Royalty Required To Pay PercentageOfRoyaltyRequiredToPay	0.01	pure
CY2011Q3	rxii	Percentage Of Fully Diluted Shares Issued Upon Completion Of Spin Off Transaction PercentageOfFullyDilutedSharesIssuedUponCompletionOfSpinOffTransaction	0.05	pure
CY2003	us-gaap	Net Income Loss NetIncomeLoss	-89000
CY2005	us-gaap	Net Income Loss NetIncomeLoss	-2209000
CY2005	rxii	Net Transactions With Parent NetTransactionsWithParent	2727000
CY2006	us-gaap	Net Income Loss NetIncomeLoss	-2405000
CY2006	rxii	Net Transactions With Parent NetTransactionsWithParent	2587000
CY2007	us-gaap	Net Income Loss NetIncomeLoss	-10990000
CY2007	rxii	Cash Contributions From Parent Company CashContributionsFromParentCompany	15679000
CY2007	rxii	Non Cash Equity Adjustments From Parent Company NonCashEquityAdjustmentsFromParentCompany	4318000
CY2007	rxii	Adjustments To Divisional Equity Share Based Compensation Requisite Service Period Recognition Value AdjustmentsToDivisionalEquityShareBasedCompensationRequisiteServicePeriodRecognitionValue	1814000
CY2009	us-gaap	Net Income Loss NetIncomeLoss	-18387000
CY2009	rxii	Cash Contributions From Parent Company CashContributionsFromParentCompany	7714000
CY2009	rxii	Non Cash Equity Adjustments From Parent Company NonCashEquityAdjustmentsFromParentCompany	-1756000
CY2009	rxii	Adjustments To Divisional Equity Share Based Compensation Requisite Service Period Recognition Value AdjustmentsToDivisionalEquityShareBasedCompensationRequisiteServicePeriodRecognitionValue	4202000
CY2010	us-gaap	Net Income Loss NetIncomeLoss	-11993000
CY2010	rxii	Cash Contributions From Parent Company CashContributionsFromParentCompany	11640000
CY2010	rxii	Non Cash Equity Adjustments From Parent Company NonCashEquityAdjustmentsFromParentCompany	-2326000
CY2010	rxii	Adjustments To Divisional Equity Share Based Compensation Requisite Service Period Recognition Value AdjustmentsToDivisionalEquityShareBasedCompensationRequisiteServicePeriodRecognitionValue	4368000
CY2011	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2551000
CY2011	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-229000
CY2011	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.28
CY2011	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6624000
CY2011	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P0Y
CY2011	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	36334413	shares
CY2011	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	4357000
CY2011	us-gaap	Depreciation And Amortization DepreciationAndAmortization	163000
CY2011	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit
CY2011	us-gaap	Operating Income Loss OperatingIncomeLoss	-12770000
CY2011	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	122000
CY2011	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-1113000
CY2011	us-gaap	Net Income Loss NetIncomeLoss	-10219000
CY2011	us-gaap	Amortization Of Leased Asset AmortizationOfLeasedAsset	53000
CY2011	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6146000
CY2011	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit
CY2011	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit
CY2011	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-10219000
CY2011	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit
CY2011	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	-79000
CY2011	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-10219000
CY2011	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount		shares
CY2011	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	6190000
CY2011	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	220000
CY2011	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-884000
CY2011	rxii	Research And Development Employee Stock Based Compensation Expense ResearchAndDevelopmentEmployeeStockBasedCompensationExpense	513000
CY2011	rxii	Research And Development Non Employee Stock Based Compensation Expense ResearchAndDevelopmentNonEmployeeStockBasedCompensationExpense	-79000
CY2011	rxii	Reclassification Of Derivative Liability Upon Elimination Of Obligation ReclassificationOfDerivativeLiabilityUponEliminationOfObligation	9249000
CY2011	rxii	Cash Contributions From Parent Company CashContributionsFromParentCompany	1500000
CY2011	rxii	Cash Contributions To Parent Company CashContributionsToParentCompany	369000
CY2011	rxii	Adjustments To Additional Paid In Capital Expenses Paid By Parent Company AdjustmentsToAdditionalPaidInCapitalExpensesPaidByParentCompany	2058000
CY2011	rxii	Net Income Loss Attributable To Predecessor Company NetIncomeLossAttributableToPredecessorCompany	-7682000
CY2011	rxii	Non Cash Equity Adjustments From Parent Company NonCashEquityAdjustmentsFromParentCompany	-8083000
CY2011	rxii	General And Administrative Employee Stock Based Compensation GeneralAndAdministrativeEmployeeStockBasedCompensation	1675000
CY2011	rxii	Predecessor Equity Instruments Issued To Other Than Employees PredecessorEquityInstrumentsIssuedToOtherThanEmployees	114000
CY2011	rxii	Adjustments To Divisional Equity Share Based Compensation Requisite Service Period Recognition Value AdjustmentsToDivisionalEquityShareBasedCompensationRequisiteServicePeriodRecognitionValue	1987000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	6441000
	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	12815000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	56182000
	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	27637000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-95922000
	us-gaap	Revenue From Grants RevenueFromGrants	97000
	us-gaap	Net Income Loss NetIncomeLoss	-88883000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	39837000
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	598000
	us-gaap	Revenues Revenues	97000
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-101698000
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-88883000
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	36619000
	rxii	Research And Development Employee Stock Based Compensation Expense ResearchAndDevelopmentEmployeeStockBasedCompensationExpense	3338000
	rxii	Research And Development Non Employee Stock Based Compensation Expense ResearchAndDevelopmentNonEmployeeStockBasedCompensationExpense	6098000
	rxii	General And Administrative Employee Stock Based Compensation GeneralAndAdministrativeEmployeeStockBasedCompensation	9498000
	rxii	Equity Instruments Issued To Other Than Employees EquityInstrumentsIssuedToOtherThanEmployees	13000
	rxii	Research And Development Intangibles Purchased From Others ResearchAndDevelopmentIntangiblesPurchasedFromOthers	6173000
	rxii	Predecessor Research And Development Intangibles Purchased From Others PredecessorResearchAndDevelopmentIntangiblesPurchasedFromOthers	3954000
	rxii	Predecessor Equity Instruments Issued To Other Than Employees PredecessorEquityInstrumentsIssuedToOtherThanEmployees	2689000
CY2004	us-gaap	Net Income Loss NetIncomeLoss	-3272000
CY2004	rxii	Net Transactions With Parent NetTransactionsWithParent	2393000
CY2008	us-gaap	Net Income Loss NetIncomeLoss	-14373000
CY2008	rxii	Cash Contributions From Parent Company CashContributionsFromParentCompany	7944000
CY2008	rxii	Non Cash Equity Adjustments From Parent Company NonCashEquityAdjustmentsFromParentCompany	750000
CY2008	rxii	Adjustments To Divisional Equity Share Based Compensation Requisite Service Period Recognition Value AdjustmentsToDivisionalEquityShareBasedCompensationRequisiteServicePeriodRecognitionValue	3824000
CY2012	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2012	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2012	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2012
CY2012	dei	Document Type DocumentType	10-K
CY2012	dei	Document Period End Date DocumentPeriodEndDate	2012-12-31
CY2012	dei	Entity Incorporation Date Of Incorporation EntityIncorporationDateOfIncorporation	2011-09-08
CY2012	dei	Entity Central Index Key EntityCentralIndexKey	0001533040
CY2012	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2012	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2012	dei	Trading Symbol TradingSymbol	RXII
CY2012	dei	Entity Registrant Name EntityRegistrantName	RXI PHARMACEUTICALS CORP
CY2012	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2012	dei	Amendment Flag AmendmentFlag	false
CY2012	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
CY2012	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	125000
CY2012	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
CY2012	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-484000
CY2012	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	12815000
CY2012	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	147000
CY2012	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div> <p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2"><i>Concentrations of Credit Risk</i> — Financial instruments that potentially subject the Company to significant concentrations of credit risk consist principally of cash and cash equivalents. The Company maintains cash balances in several accounts with one bank, which at times are in excess of federally insured limits. The Company’s investment policy requires investment in any debt securities be at least “investment grade” by national ratings services. All of the non-interest bearing cash balances were fully insured at December 31, 2012 due to temporary federal program in effect from December 31, 2010 through December 31, 2012. Under the program, there is no limit to the amount of insurance for eligible accounts. Beginning 2013, insurance coverage will revert to $250,000 per depositor at each financial institution, and the non-interest bearing cash balances may again exceed federally insured limits. As of December 31, 2012, the Company did not have any balances in excess of federally insured limits.</font></p> </div>
CY2012	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div> <p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2"><i>Reclassifications</i> — Certain prior period items have been reclassified to conform to the current year presentation, which affect balance sheet presentation only.</font></p> </div>
CY2012	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.19
CY2012	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	16000
CY2012	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	63847938	shares
CY2012	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10451000
CY2012	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Lower Range Limit ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit	0.65
CY2012	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	13000
CY2012	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P9Y4M21D
CY2012	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-298000
CY2012	us-gaap	Operating Loss Carryforwards Expiration Dates OperatingLossCarryforwardsExpirationDates	2031
CY2012	us-gaap	Interest Paid InterestPaid	30000
CY2012	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	137213630	shares
CY2012	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	8000
CY2012	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	2172000
CY2012	us-gaap	Increase Decrease In Due To Other Related Parties Current IncreaseDecreaseInDueToOtherRelatedPartiesCurrent	597000
CY2012	us-gaap	Share Based Compensation ShareBasedCompensation	968000
CY2012	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.10
CY2012	us-gaap	Depreciation And Amortization DepreciationAndAmortization	147000
CY2012	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	4624000
CY2012	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit
CY2012	us-gaap	Debt Instrument Maturity Date Description DebtInstrumentMaturityDateDescription	Three months or less
CY2012	us-gaap	Operating Income Loss OperatingIncomeLoss	-12975000
CY2012	us-gaap	Revenue From Grants RevenueFromGrants	97000
CY2012	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	968000
CY2012	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	1000000
CY2012	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	224000
CY2012	us-gaap	Nature Of Operations NatureOfOperations	<div> <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><b>1. Nature of Business</b></font></p> <p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">Prior to April 13, 2011, Galena Biopharma, Inc. (“<b>Galena</b>” or the “<b>Parent Company</b>”) (formerly known as RXi Pharmaceuticals Corporation) was engaged primarily in conducting discovery research and preclinical development activities based on RNAi, and Galena’s financial statements for periods prior to April 13, 2011 reflected solely the assets, liabilities and results of operations attributable to Galena’s RNAi-based assets, liabilities and results of operations. On April 13, 2011, Galena broadened its strategic direction by adding the development and commercialization of cancer therapies that utilize peptide-based immunotherapy products, including a main product candidate, NeuVax, for the treatment of various cancers. On September 24, 2011, Galena contributed to RXi Pharmaceuticals Corporation (“<b>RXi</b>,” “<b>Registrant</b>,” or the “<b>Company</b>”), a newly formed subsidiary of Galena, substantially all of Galena’s RNAi-related technologies and assets. The newly formed RXi was incorporated on September 8, 2011 with the issuance of 100 initial shares at a price of $0.01 per share, for total consideration of $1.00. RXi was not engaged in any activities other than its initial incorporation from September 8, 2011 to September 23, 2011.</font></p> <p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">As a result of these transactions, certain historical financial information for the fiscal year ended December 31, 2011, as well as the cumulative period from inception (January 1, 2003) through December 31, 2012, has been “carved out” of the financial statements of Galena (the “Predecessor”) for such periods, and includes “carved out” activities through September 23, 2011. Such financial information is limited to Galena’s RNAi-related activities, assets and liabilities only, and excludes activities, assets and liabilities that are attributable to Galena’s cancer therapy activities.</font></p> <p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">The carved-out financial information includes both direct and indirect expenses. The historical direct expenses consist primarily of the various costs for technology license agreements, sponsored research agreements, fees paid to scientific advisors and employee expenses of employees directly involved in RNAi-related activities. Indirect expenses represent expenses incurred by Galena that were allocable to the RNAi business. The indirect expenses are based upon: (1) estimates of the percentage of time spent by Galena employees working on RNAi business matters, and (2) allocations of various expenses associated with the employees, including salary, benefits, rent associated with the employees’ office space, accounting and other general and administrative expenses. The percentage of time spent by Galena employees was multiplied by these allocable expenses to arrive at the total employee expenses allocable to the RNAi business and reflected in the carved out financial statements.</font></p> <p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">Management believes the assumptions underlying the carve-out financial information are reasonable; however, the financial position, expenses and cash flows may have been materially different if the RNAi business had operated as a stand-alone entity during the periods presented.</font></p> <p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">The financial statements reflect the recapitalization of our Predecessor’s divisional deficit as of September 24, 2011, the date Galena contributed assets to RXi. The recapitalization on September 24, 2011 reflects the elimination of the Predecessor’s divisional deficit of $1,730,000 and the issuance of 100,439,841 shares of RXi common stock, par value $0.0001, with a corresponding charge of $1,740,000 to deficit accumulated since incorporation and increase in par value of $10,000. No amounts were reflected in additional paid-in capital due to the divisional deficit at the date of the recapitalization.</font></p> <p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">RXi was formed on September 8, 2011 and was not engaged in any activities other than its initial incorporation from September 8, 2011 to September 23, 2011. The RNAi business operated as a division of Galena prior to September 24, 2011. The balance of $17,157,000 in deficit accumulated since the development stage at December 31, 2012 includes RXi’s net loss of $15,417,000 for the period September 24, 2011 to December 31, 2012 and the Predecessor’s cumulative net loss of $73,466,000 through September 23, 2011 offset by cash and non-cash equity transactions of $71,726,000.</font></p> <p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">To date, RXi’s principal activities, including that of its Predecessor, have consisted of conducting discovery research and preclinical development activities utilizing its RNAi therapeutic platform, acquiring RNAi technologies and patent rights through exclusive, co-exclusive and non-exclusive licenses, recruiting an RNAi-focused management and scientific/clinical advisory team, capital raising activities and conducting business development activities aimed at establishing research and development partnerships with pharmaceutical and larger biotechnology companies.</font></p> <p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">The Company and the Predecessor have generated significant losses since inception. Additionally, the Company has not generated any product revenues, nor are any revenues expected for the foreseeable future, and as such the Company is considered a development stage company for accounting purposes. The Company expects to incur significant operating losses for the foreseeable future while the Company advances its future product candidates from discovery through preclinical studies and clinical trials and seeks regulatory approval and potential commercialization, even if the Company is collaborating with pharmaceutical and larger biotechnology companies. The Company will need to generate significant revenues to achieve profitability and may never do so. On September 24, 2011, RXi entered into a contribution agreement with Galena pursuant to which:</font></p> <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 6px">  </p> <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td width="5%"><font size="1"> </font></td> <td valign="top" width="2%" align="left"><font style="FONT-FAMILY: Times New Roman" size="2">•</font></td> <td valign="top" width="1%"><font size="1"> </font></td> <td valign="top" align="left"> <p align="left"><font style="FONT-FAMILY: Times New Roman" size="2">Galena assigned and contributed to RXi substantially all of its RNAi-related technologies and assets, which consist primarily of novel RNAi compounds and licenses from Dharmacon, Inc., Northwestern University, the Carnegie Institute of Washington, and the University of Massachusetts Medical School relating to its RNAi technologies, as well as the lease of its former Worcester, Massachusetts laboratory facility, fixed assets and other equipment located at the facility and its employment arrangements with certain scientific, corporate and administrative personnel who became employees of RXi, as well as research grants from the National Institute of Neurological Disorders and Stroke, National Institute of Allergy and Infectious Diseases, and the National Institute of General Medical Sciences of approximately $800,000 that were subject to the approval of the granting institutions, which was received in 2012; and</font></p> </td> </tr> </table> <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 6px">  </p> <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td width="5%"><font size="1"> </font></td> <td valign="top" width="2%" align="left"><font style="FONT-FAMILY: Times New Roman" size="2">•</font></td> <td valign="top" width="1%"><font size="1"> </font></td> <td valign="top" align="left"> <p align="left"><font style="FONT-FAMILY: Times New Roman" size="2">RXi agreed to assume certain accrued expenses of the RXI-109 development program and all future obligations under the contributed licenses, employment arrangements and other agreements, and RXi agreed to make future milestone payments to Galena of up to $45 million, consisting of two one-time payments of $15 million and $30 million, respectively, if RXi achieves annual net sales equal to or greater than $500 million and $1 billion, respectively, of any covered products that may be developed with the contributed RNAi technologies.</font></p> </td> </tr> </table> <p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">On September 24, 2011, RXi entered into a securities purchase agreement (the “<b>Series A SPA</b>”) with Galena, Tang Capital Partners, LP (“<b>TCP</b>”) and RTW Investments, LLC (“<b>RTW</b>”) pursuant to which:</font></p> <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 6px">  </p> <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td width="5%"><font size="1"> </font></td> <td valign="top" width="2%" align="left"><font style="FONT-FAMILY: Times New Roman" size="2">•</font></td> <td valign="top" width="1%"><font size="1"> </font></td> <td valign="top" align="left"> <p align="left"><font style="FONT-FAMILY: Times New Roman" size="2">TCP and RTW agreed to purchase a total of 9,500 shares of RXi’s Series A Convertible Preferred Stock (the “<b>Series A Preferred Stock</b>”), for an aggregate purchase price of $9,500,000, at the closing of the spin-off transaction (see below) and to lend RXi up to $1,500,000 to fund RXi’s operations prior to the closing, which would be applied against the $9,500,000 purchase price of the Series A Preferred Stock. The outstanding principal and accrued interest on the loan(s), along with the receipt of the remaining $9,500,000 purchase price, was converted into Series A Preferred Stock at the closing at a conversion price of $1,000 per share;</font></p> </td> </tr> </table> <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 6px">  </p> <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td width="5%"><font size="1"> </font></td> <td valign="top" width="2%" align="left"><font style="FONT-FAMILY: Times New Roman" size="2">•</font></td> <td valign="top" width="1%"><font size="1"> </font></td> <td valign="top" align="left"> <p align="left"><font style="FONT-FAMILY: Times New Roman" size="2">RXi agreed that the Series A Preferred Stock would be convertible by TCP or RTW at any time into shares of RXi common stock, except to the extent that the holder would own more than 9.999% of the shares of RXi common stock outstanding immediately after giving effect to such conversion;</font></p> </td> </tr> </table> <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 6px">  </p> <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td width="5%"><font size="1"> </font></td> <td valign="top" width="2%" align="left"><font style="FONT-FAMILY: Times New Roman" size="2">•</font></td> <td valign="top" width="1%"><font size="1"> </font></td> <td valign="top" align="left"> <p align="left"><font style="FONT-FAMILY: Times New Roman" size="2">Galena contributed $1.5 million of cash to RXi;</font></p> </td> </tr> </table> <p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px; FONT-SIZE: 1px">  </p> <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td width="5%"><font size="1"> </font></td> <td valign="top" width="2%" align="left"><font style="FONT-FAMILY: Times New Roman" size="2">•</font></td> <td valign="top" width="1%"><font size="1"> </font></td> <td valign="top" align="left"> <p align="left"><font style="FONT-FAMILY: Times New Roman" size="2">Galena agreed to distribute to its stockholders 8% of the fully-diluted shares of common stock of RXi that will be outstanding immediately upon the completion of the spin-off transaction; and</font></p> </td> </tr> </table> <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 6px">  </p> <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td width="5%"><font size="1"> </font></td> <td valign="top" width="2%" align="left"><font style="FONT-FAMILY: Times New Roman" size="2">•</font></td> <td valign="top" width="1%"><font size="1"> </font></td> <td valign="top" align="left"> <p align="left"><font style="FONT-FAMILY: Times New Roman" size="2">RXi agreed to reimburse, upon completion of the spin-off transaction, Galena for up to a total of $300,000, and TCP and RTW for a total of up to $100,000, of transaction costs relating to the contribution agreement with Galena, the Series A SPA summarized above and the transactions contemplated by those agreements.</font></p> </td> </tr> </table> <p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">On April 27, 2012, the date of completion of RXi’s spinoff from Galena, the Company issued 9,500 of Series A Preferred Stock to TCP and RTW upon the conversion of approximately $1.0 million in principal and accrued interest under the bridge notes and the receipt of the remaining $8.5 million from TCP and RTW, as provided for in the Series A SPA. At the closing of the spin-off transaction, RXi reimbursed Galena and TCP $300,000 and $100,000, respectively, for transaction related expenses.</font></p> <p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">As part of the transactions contemplated by the contribution agreement and Series A SPA, on September 24, 2011, RXi entered into an agreement with Advirna, LLC (“<b>Advirna</b>”), a company affiliated with the Company’s former Senior Vice President and Chief Scientific Officer, pursuant to which:</font></p> <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 6px">  </p> <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td width="5%"><font size="1"> </font></td> <td valign="top" width="2%" align="left"><font style="FONT-FAMILY: Times New Roman" size="2">•</font></td> <td valign="top" width="1%"><font size="1"> </font></td> <td valign="top" align="left"> <p align="left"><font style="FONT-FAMILY: Times New Roman" size="2">Advirna assigned to RXi its existing patent and technology rights related to sd-rxRNA technology in exchange for RXi’s agreement to pay Advirna an annual $100,000 maintenance fee and a one-time $350,000 milestone payment upon the future issuance of the first patent with valid claims covering the assigned patent and technology rights;</font></p> </td> </tr> </table> <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 6px">  </p> <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td width="5%"><font size="1"> </font></td> <td valign="top" width="2%" align="left"><font style="FONT-FAMILY: Times New Roman" size="2">•</font></td> <td valign="top" width="1%"><font size="1"> </font></td> <td valign="top" align="left"> <p align="left"><font style="FONT-FAMILY: Times New Roman" size="2">RXi will also be required to pay a 1% royalty to Advirna for any licensing revenue received by RXi with respect to future licensing of the assigned Advirna patent and technology rights;</font></p> </td> </tr> </table> <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 6px">  </p> <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td width="5%"><font size="1"> </font></td> <td valign="top" width="2%" align="left"><font style="FONT-FAMILY: Times New Roman" size="2">•</font></td> <td valign="top" width="1%"><font size="1"> </font></td> <td valign="top" align="left"> <p align="left"><font style="FONT-FAMILY: Times New Roman" size="2">RXi has granted back to Advirna a license under the assigned patent and technology for fields of use outside the fields of human therapeutics and diagnostics; and</font></p> </td> </tr> </table> <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 6px">  </p> <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td width="5%"><font size="1"> </font></td> <td valign="top" width="2%" align="left"><font style="FONT-FAMILY: Times New Roman" size="2">•</font></td> <td valign="top" width="1%"><font size="1"> </font></td> <td valign="top" align="left"> <p align="left"><font style="FONT-FAMILY: Times New Roman" size="2">RXi agreed to issue to Advirna, upon the completion of the spin-off transaction, shares of RXi’s common stock equal to approximately 5% of the fully diluted shares of RXi common stock assuming the conversion in full of all outstanding Series A Preferred Stock. Accordingly, at the date of the completion of the spin-off, the Company issued 41,849,934 shares of common stock to Advirna. The Company recorded -research and development expense of $6,173,000 to recognize the fair value of the common shares issued in exchange for the sd-rxRNA patent and technology rights assigned to RXi by Advirna.</font></p> </td> </tr> </table> <p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">On March 6, 2013, RXi entered into a common stock purchase agreement (the “<b>Common Stock SPA</b>”) pursuant to which RXi agreed to issue 112,956,011 shares of common stock at a price of $0.145 per share. The gross proceeds from the offering, which closed on March 12, 2013, were approximately $16.4 million, and the net proceeds, after payment of commissions, were approximately $16.0 million. The Company believes that its existing cash and cash equivalents will be sufficient to fund the Company’s operations, including the planned Phase 2 program for RXI-109, into fiscal 2015.</font></p> <p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">We expect to incur significant operating losses as we advance our product candidates through the drug development and regulatory process. We have generated significant losses to date, have not generated any product revenue to date and may not generate product revenue in the foreseeable future, if ever. In the future, RXi will be dependent on obtaining funding from third parties, such as proceeds from the issuance of debt, sale of equity, funded research and development programs and payments under partnership and collaborative agreements, in order to maintain RXi’s operations and meet RXi’s obligations to licensors. There is no guarantee that debt, additional equity or other funding will be available to the Company on acceptable terms, or at all. If the Company fails to obtain additional funding when needed, RXi would be forced to scale back, or terminate the Company operations or to seek to merge with or to be acquired by another company.</font></p> </div>
CY2012	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y4M24D
CY2012	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	29000
CY2012	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	224000
CY2012	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-2387000
CY2012	us-gaap	Net Income Loss NetIncomeLoss	-12880000
CY2012	us-gaap	Temporary Equity Accretion To Redemption Value TemporaryEquityAccretionToRedemptionValue	-9500000
CY2012	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
CY2012	us-gaap	Amortization Of Leased Asset AmortizationOfLeasedAsset	19000
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod		shares
CY2012	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2621000
CY2012	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	9670000
CY2012	us-gaap	Dividends Preferred Stock DividendsPreferredStock	3315000
CY2012	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit
CY2012	us-gaap	Revenues Revenues	97000
CY2012	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
CY2012	us-gaap	Proceeds From Contributions From Parent ProceedsFromContributionsFromParent	699000
CY2012	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Upper Range Limit ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit	7.50
CY2012	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit
CY2012	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	8500000
CY2012	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	26000
CY2012	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-30000
CY2012	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	500000
CY2012	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	6173000
CY2012	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	15000
CY2012	us-gaap	Stock Issued During Period Value Stock Dividend StockIssuedDuringPeriodValueStockDividend	3315000
CY2012	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	13000
CY2012	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-25695000
CY2012	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit
CY2012	us-gaap	Preferred Stock Redemption Discount PreferredStockRedemptionDiscount	9500000
CY2012	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	2000
CY2012	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	114000
CY2012	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-12880000
CY2012	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	775210022	shares
CY2012	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	138000
CY2012	us-gaap	Use Of Estimates UseOfEstimates	<div> <p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2"><i>Uses of estimates in preparation of financial statements</i> — The preparation of financial statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ materially from those estimates.</font></p> </div>
CY2012	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	223000
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.07
CY2012	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	29000
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0000	pure
CY2012	us-gaap	Dividends Preferred Stock Paidinkind DividendsPreferredStockPaidinkind	2865000
CY2012	us-gaap	Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings	-3315000
CY2012	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	33000
CY2012	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-1903000
CY2012	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	3746000
CY2012	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5062000
CY2012	rxii	Future Milestone Payments FutureMilestonePayments	45000000
CY2012	rxii	Entity Incorporation Date Of Incorporation End Date EntityIncorporationDateOfIncorporationEndDate	2011-09-23
CY2012	rxii	Preferred Stock Beneficial Conversion Feature PreferredStockBeneficialConversionFeature	9500000
CY2012	rxii	Research And Development Employee Stock Based Compensation Expense ResearchAndDevelopmentEmployeeStockBasedCompensationExpense	418000
CY2012	rxii	Research And Development Non Employee Stock Based Compensation Expense ResearchAndDevelopmentNonEmployeeStockBasedCompensationExpense	114000
CY2012	rxii	Patent And Technology Rights Expenses PatentAndTechnologyRightsExpenses	6173000
CY2012	rxii	Adjustments To Additional Paid In Capital Expenses Paid By Parent Company AdjustmentsToAdditionalPaidInCapitalExpensesPaidByParentCompany	699000
CY2012	rxii	Maximum Annual Net Sales Achieve In First Payment MaximumAnnualNetSalesAchieveInFirstPayment	500000000
CY2012	rxii	Maximum Annual Net Sales Achieve In Second Payment MaximumAnnualNetSalesAchieveInSecondPayment	1000000000
CY2012	rxii	Non Cash Equity Transactions NonCashEquityTransactions	71726000
CY2012	rxii	Future Milestone Payments First Payment FutureMilestonePaymentsFirstPayment	15000000
CY2012	rxii	Future Milestone Payments Second Payment FutureMilestonePaymentsSecondPayment	30000000
CY2012	rxii	General And Administrative Employee Stock Based Compensation GeneralAndAdministrativeEmployeeStockBasedCompensation	436000
CY2012	rxii	Forfeiture Rate For Options Granted To Directors ForfeitureRateForOptionsGrantedToDirectors	0.00	pure
CY2012	rxii	Forfeiture Rate For Options Granted To Employees ForfeitureRateForOptionsGrantedToEmployees	0.050	pure
CY2012	rxii	Stock Issued During Period Shares Issued For Exchange Of Patent And Technology Rights StockIssuedDuringPeriodSharesIssuedForExchangeOfPatentAndTechnologyRights	41849934	shares
CY2012	rxii	Distribution Ratio Description DistributionRatioDescription	One share of RXi common stock for every one share of Galena common stock.
CY2012	rxii	Equity Instruments Issued To Other Than Employees EquityInstrumentsIssuedToOtherThanEmployees	13000
CY2012	rxii	Research And Development Intangibles Purchased From Others ResearchAndDevelopmentIntangiblesPurchasedFromOthers	6173000

Files In Submission

Name	View Source	Status
0001193125-13-133515-index-headers.html	Edgar Link	pending
0001193125-13-133515-index.html	Edgar Link	pending
0001193125-13-133515.txt	Edgar Link	pending
0001193125-13-133515-xbrl.zip	Edgar Link	pending
d461259d10k.htm	Edgar Link	pending
d461259dex231.htm	Edgar Link	pending
d461259dex311.htm	Edgar Link	pending
d461259dex321.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
g461259g13u62.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
rxii-20121231.xml	Edgar Link	completed
rxii-20121231.xsd	Edgar Link	pending
rxii-20121231_cal.xml	Edgar Link	unprocessable
rxii-20121231_def.xml	Edgar Link	unprocessable
rxii-20121231_lab.xml	Edgar Link	unprocessable
rxii-20121231_pre.xml	Edgar Link	unprocessable
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PHIO
Phio Pharmaceuticals Corp Stock $phio

2013 Q1 Form 10-K Financial Statement

#000119312513133515 Filed on March 29, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PHIO Phio Pharmaceuticals Corp Stock $phio

2013 Q1 Form 10-K Financial Statement

#000119312513133515 Filed on March 29, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PHIO
Phio Pharmaceuticals Corp Stock $phio